Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a consensus recommendation of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $0.67.

SNSS has been the subject of a number of analyst reports. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Tuesday, March 10th. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Wednesday, May 13th. Oppenheimer lowered shares of Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 23rd. Wells Fargo & Co lowered shares of Sunesis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $3.00 to $1.00 in a research note on Wednesday, March 11th. Finally, HC Wainwright reduced their price target on shares of Sunesis Pharmaceuticals from $1.00 to $0.50 and set a “neutral” rating for the company in a research note on Friday, May 8th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BCS Wealth Management bought a new stake in shares of Sunesis Pharmaceuticals in the 4th quarter worth approximately $28,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Sunesis Pharmaceuticals in the 1st quarter worth approximately $42,000. Geode Capital Management LLC raised its holdings in shares of Sunesis Pharmaceuticals by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 632,647 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 16,913 shares during the period. Burrage Capital Management LLC raised its holdings in shares of Sunesis Pharmaceuticals by 24.5% during the first quarter. Burrage Capital Management LLC now owns 682,586 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 134,358 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Sunesis Pharmaceuticals by 96.9% during the first quarter. BlackRock Inc. now owns 2,290,180 shares of the biopharmaceutical company’s stock valued at $950,000 after acquiring an additional 1,127,038 shares during the period. Institutional investors and hedge funds own 56.70% of the company’s stock.

Shares of NASDAQ:SNSS traded up $0.00 during trading on Tuesday, reaching $0.29. 3,491,300 shares of the company’s stock traded hands, compared to its average volume of 2,565,270. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.32. Sunesis Pharmaceuticals has a 12 month low of $0.20 and a 12 month high of $1.13. The company has a 50 day moving average of $0.43 and a 200-day moving average of $0.51. The stock has a market capitalization of $31.75 million, a P/E ratio of -1.15 and a beta of 1.71.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.15 million. Equities research analysts predict that Sunesis Pharmaceuticals will post -0.22 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Further Reading: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.